Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | LNPEP | Q9UIQ6 | 6/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.56 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | MDM4 | O15151 | 1/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.54 |
| ▸ | TACR3 | P29371 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.52 |
| ▸ | HPGDS | O60760 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5921742 | 1.00 | GAA (0.64) | GAARAB9ALNPEPALDH1A1TSHR | |
| SCHEMBL13885677 | 0.87 | GAA (0.73) | GAARAB9ALNPEPALDH1A1TSHR | |
| SCHEMBL5921641 | 0.87 | GAA (0.67) | GAARAB9ALNPEPALDH1A1ERAP2 | |
| SCHEMBL5921637 | 0.87 | GAA (0.67) | GAARAB9ALNPEPALDH1A1ERAP2 | |
| SCHEMBL5921683 | 0.86 | GAA (0.65) | GAARAB9ALNPEPALDH1A1TSHR | |
| SCHEMBL5921680 | 0.86 | GAA (0.65) | GAARAB9ALNPEPALDH1A1TSHR | |
| SCHEMBL5921789 | 0.84 | GAA (0.59) | GAARAB9ALNPEPALDH1A1LMNA | |
| SCHEMBL5921780 | 0.84 | GAA (0.59) | GAARAB9ALNPEPALDH1A1LMNA | |
| SCHEMBL6030105 | 0.84 | GAA (0.68) | GAARAB9ALNPEPALDH1A1TSHR | |
| SCHEMBL13525006 | 0.83 | GAA (0.70) | GAARAB9ALNPEPALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060166989-A1 | 2-naphthamide derivatives | BAYER HEALTHCARE AG (DE) | 2006-07-27 | — | — | US | disclosed |
| EP-1515941-A1 | 2-NAPHTHAMIDE DERIVATIVES | Bayer HealthCare AG (DE) | 2005-03-23 | — | — | EP | disclosed |
| WO-2003106402-A1 | 2-NAPHTAMIDE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166989-A1 | 2-naphthamide derivatives | BPHL, F2RL1, HRH2 | GAA 1846/4885RAB9A 2535/4885LNPEP 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.